OTE welcomes new editor

Article

Ophthalmology Times Europe founding editor, Fedra Pavlou, is to become Editor-in-Chief of Pharmaceutical Technology Europe, another of Advanstar's publications. Pamela Brook joins the team as editor of OTE, with immediate effect.

Ophthalmology Times Europe founding editor, Fedra Pavlou, is to become Editor-in-Chief of Pharmaceutical Technology Europe, another of Advanstar's publications. Pamela Brook joins the team as editor of OTE, with immediate effect. However, the OTE portfolio will continue to benefit from Fedra's expertise, as she will continue to contribute her valuable knowledge at various times throughout this coming year. Commenting on the changes Fedra said: "It has been a pleasure to be involved in such an exciting and rewarding industry and thank you to all our readers for your input, feedback and kind words since our launch."

Incoming editor, Pamela Brook said: "No reader of OTE can doubt that it is Fedra, and her team's, hard work, commitment and extensive knowledge of the industry that has made Ophthalmology Times Europe the success it is today. We all wish her every success in her new role. In turn, I am extremely pleased to be joining OTE at what promises to be both a changing and, subsequently, challenging time."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.